Urotensin II: a new pharmacologic target in the treatment of cardiovascular disease.
Urotensin II was first identified over 30 years ago as a potent vasoconstrictor, and the identification of its receptor in the heart, lungs, blood vessels, and brain have made it a potential target for human pharmacotherapy. Current research would suggest that urotensin II plays a major role in the pathophysiology of various cardiovascular disease entities. This article discusses the biologic effects of urotensin under normal and pathophysiologic conditions, and reviews the research experiences with synthetic urotensin blockers in the treatment of various cardiovascular illnesses.
Desai
Nirav
N
Department of Medicine, UCLA Medical Center, Los Angeles, California, USA.
Sajjad
Jameel
J
Frishman
William H
WH
D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D009200:Myocardial Contraction; D011804:Quinolines / Q000494:pharmacology; D043562:Receptors, G-Protein-Coupled / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013449:Sulfonamides / Q000494:pharmacology; D014508:Urea / Q000031:analogs & derivatives / Q000494:pharmacology; D014579:Urotensins / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism*; D014662:Vasoconstrictor Agents; D000096926:Benzenesulfonamides
D015415:Biomarkers; D011804:Quinolines; D043562:Receptors, G-Protein-Coupled; D013449:Sulfonamides; D014508:Urea; D014579:Urotensins; D014662:Vasoconstrictor Agents; C513816:SB-611812; D000096926:Benzenesulfonamides; C121697:UTS2R protein, human; C029677:urotensin II; C493249:1-(2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl)-3-(2-methylquinolin-4-yl)urea